Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Jonathan Harris et al.|Journal of Surgical Oncology|2008Cited by 419
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132Dian Wang, Burton Eisenberg, Margaret von Mehren et al.|Annals of Surgical Oncology|2011Cited by 202
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C. Widemann, John P. Perentesis, Rashmi Chugh et al.|Sarcoma|2019Cited by 74